AIHealthcare Analytics

Knowledge Wiki

Wiki › Massive Bio and FOMAT — AI Prescreening for Oncology Clinical Trials

Massive Bio and FOMAT — AI Prescreening for Oncology Clinical Trials

ENTITY
Rev 1 Jul 22, 2026 15:34 UTC 1 sources

Overview Massive Bio has partnered with FOMAT to pilot AI-based prescreening for oncology clinical trials across a community-focused research network in the United States. The collaboration targets a persistent challenge in oncology research: identifying eligible trial participants efficiently in community (non-academic) settings. AI Prescreening Approach Massive Bio's AI platform analyzes patient data against clinical trial eligibility criteria to identify potentially eligible patients before manual review. This automated prescreening reduces the time and cost of patient identification, which is a major bottleneck in clinical trial recruitment—particularly for complex oncology trials with extensive inclusion/exclusion criteria. Community Research Network Focus FOMAT operates a community-focused research network, making this partnership notable for its emphasis on community rather than academic medical center settings. Community-based trial enrollment is critical for ensuring that trial populations reflect the diversity of patients who will ultimately receive approved therapies. Significance The Massive Bio-FOMAT collaboration exemplifies the growing application of AI to clinical trial operations—a domain where AI can meaningfully accelerate drug development timelines by improving recruitment efficiency without compromising eligibility standards. ---

Sources: harvested
🔒

Subscribe to read full wiki analysis

Full wiki content — including source provenance, contradiction tracking, related pages, and analyst notes — is available to Subscriber members.

View Plans & Subscribe

New users get a 7-day trial — no credit card required.

← Back to Wiki Index